PTPRC and neoplasm: The EEDNV group demonstrated the highest ratio of tumor-infiltrating effector T cells (CD45+CD3+CD8+IFN-γ+), reaching up to 19.9 ± 2.1%, which significantly activated antitumor immunity and prevented tumor inhibition (Supplementary Figure S11).